MATRIXLABS

Matrix Laboratories Limited has informed the Exchange regarding a press release dated October 05, 2005, titled 'Matrix Laboratories completes the acquisition of Docpharma by obtaining 95.51% stake in the public takeover bid;Squeeze-out bid for all remaining shares not yet tendered'. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange regarding a Press Release dated September 26, 2005 titled "Matrix enters Definitive Agreement for acquiring controlling stake in Mchem Group, China". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange regarding a Press Release dated September 23, 2005 titled "Matrix and Aspen, South Africa, finalize Strategic business relationship".The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange regarding a Press Release dated September 20,2005 titled "Matrix acquires 43% stake in Explora, Switzerland- Strategic initiative to gain access to technology platforms and product portfolios such as anti-cancer and corticosteroids". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the Members of the Company at their AGM held on August 25,2005 considered and unanimously approved all the resolutions of the Notice including the following items :- a) Payment of Dividend @ Rs.1.20 per equity shares of Rs. 2/- each.b) Delisting of Equity Shares from Hyderabad Stock Exchange. The company has further informed the Exchange that with respect to the Postal Ballot conducted for giving Guarantee(s) to or in respect of subsidiaries of the Company pursuant to Section 372A of the Companies Act, 1956, the Results of the Postal B

Matrix Laboratories Limited has informed the Exchange that the BODs vide circular resolution dated August 25, 2005 appointed Mr. Rajiv Malik as an Additional Director and Chief Executive Officer of the Company.

Matrix Laboratories Limited has informed the Exchange that the Compensation Committee at its meeting held on July 28, 2005 have granted another 10,85,000 employee stock options of Rs. 2/- each to the eligible members of the Scheme under ESOP 2004.

Matrix Laboratories Limited has informed the Exchange that the Board of Directors at their meeting held on July 28, 2005 considered and approved the following business: 1) Appointment of Mr. Rajiv Malik as an Additional Director and Chief Executive Officer of the Company. 2) Accepted the resignation submitted by Dr. C. Satyanarayana as Chief Operating Officer and confirmed his continuation as Non Executive Director on the Board of the Company. 3) Accepted the resignation submitted by Mr. N. Prasad as Chief Executive Officer and confirmed his continuation as Executive Chairman of the Company. 4

Matrix Laboratories Limited has informed the Exchange regarding a Press Release dated July 28, 2005, titled "Matrix reports Rs.154 crore sales and Rs.25 crore PAT for Q1 FY 05-06; New corporate R&D Center at Bollaram inaugurated; US DMFs increased to 50, number of product innovation patens increased to 74; Acquisition of 22 per cent controlling stake in Docpharma, Belgium, completed, draft prospects for the open offer filed with BFIC; FDF facility to initiate ANDA batches in August; Medikon Galenicals, the JV company, commenced Dossier filing in Europe". The details of the press release shall

Matrix Laboratories Limited has informed the Exchange that the BOD's through Circular Resolution have decided to Call-Off Merger plans with Strides Arcolab Limited as both the Companies were unable to reach an agreement on valuation. The details of the press release titled "Matrix and Strides Call-Off Merger Plans", issued by the Company, shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange regarding a Press Release dated July 22, 2005 titled "Matrix secured WHO, Geneva, GMP certification for two facilities". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange regarding a Press Release dated July 08, 2005 titled "Matrix Laboratories completes share purchase of controlling stake in Docpharma". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange regarding a Press Release dated July 11, 2005, titled "Matrix announces changes in Executive Management structure, Mr. Rajiv Malik to be the new CEO". These changes, wherever necessary, are subject to the approval of the Board. The next Board Meeting is scheduled to be held on July 28, 2005. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has submitted to the Exchange a copy of the minutes of the Postal Ballot, the results of which are declared on June 14, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the Board of Directors at their meeting held on June 19, 2005, have proposed for Voluntary Delisting from the Hyderabad Stock Exchange Limited, subject to the approval of the shareholders of the Company by way of Special resolution, in the ensuing AGM schedule to be held on August 25, 2005 and other applicable provisions of Securities and Exchange Board of India (Delisting of Securities) Guidelines 2003.

Matrix Laboratories Limited has informed the Exchange that the Company has issued a Press Release dated June 21, 2005 titled "Mr. Sanjeev Sethi joins as Sr. Vice President (Pharmaceuticals & Technical Services)". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the BODs at their meeting held on June 19,2005 have approved to acquire a controlling stake in Docpharma NV,Belgium.The details of the press release issued by the company regarding the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the results of postal ballot conducted pursuant to the provisions of Section 192A of the Companies Act, 1956 read with Companies (Passing of resolution by postal ballot) Rules 2001 in respect to the Resolutions for the following business: I) Raising of funds through debt and / or equity related instruments. II) Enhancement of borrowing limits. III) Transfer of Undertaking, had been declared on June 14, 2005. The results are as follows: {1} Resolution No.1 :- 1) No. of Valid Postal Ballot forms received - 2417; 2) Votes in favour of the

Matrix Laboratories Limited has informed the Exchange that the BOD's at their meeting held on June 01, 2005, considered / approved the following business: 1) Fixed Book closure dates from August 22, 2005 to August 25, 2005 (both days inclusive) for payment of dividend and AGM; 2) To convene and conduct AGM of the Company on August 25, 2005.

Matrix Laboratories Limited has informed the Exchange that the Company has issued a press release titled 'Matrix to pay 60% dividend, net at Rs.130 cr for FY -05'. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the Board of Directors at their meeting held on June 01, 2005 considered/approved the following business: 1) Approved in principle merger of Strides Arcolab Limited with Matrix Laboratories Limited. The proposed merger is subject to a valuation exercise to be conducted by an independent firm of Chartered Accountants, while the two companies will conduct due diligence of each others business. The Boards of the two companies expect to meet within 6 to 8 weeks to finalize the terms of the plan. The merger will be effective April 01, 2005

Matrix Laboratories Limited has informed the Exchange that pursuant to Section 192A of the Companies Act, 1956 read with the Companies (Passing of Resolution by Postal Ballot) Rules, 2001, consent of the members for the following items is sought to be obtained by means of Postal Ballot: 1) Raising of funds through debt and/or equity related instruments; 2) Enhancement of borrowing limits; 3) Transfer of undertaking. The Board of Directors has appointed Mr. P. Jagannatham, Partner of M/s. Puttaparthi Jagannatham & Co., Company Secretaries, as the scrutinizer (the "Scrutinizer") for conducting t

Matrix Laboratories Limited has informed the Exchange that the Board of Directors at their meeting held on April 26, 2005, considered and approved the following business: 1) Reconstitution of Audit Committee; 2) Allotment of 38,000 equity shares of Rs.2/- each annulling the forfeiture; 3) Approval for raising funds of approximately USD 200 Million by way of debt and / or equity related instruments / Global Depository Receipts / American Depository Receipts / Foreign Currency Convertible Bonds, subject to the approval of shareholders and other requisite approvals; 4) Acceptance of Resignation o

Matrix Laboratories Limited has informed the Exchange that the Company has received disclosures from Mr. N. Prasad, Chairman & Chief Executive Officer regarding the sale of shares of the Company. The details of the same are as follows: 1) Mr. N. Prasad has sold 4,00,000 shares and his shareholding after the said sale is 1,76,70,010 shares aggregating to 11.80% of the share capital of Matrix Laboratories Limited; 2) Mr. N. Prasad HUF has sold 6,00,000 shares and his shareholding after the said sale is 6,00,000 shares aggregating to 0.40% of the share capital of Matrix Laboratories Limited. The

Matrix Laboratories Limited has submitted to the Exchange the Annual Disclosure of the shareholdings of Directors / Employees of the Company in Matrix Laboratories Limited as on March 31, 2005. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the company has issued a press release dated April 19,2005 titled "US FDA approval for Kazipally facility". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the Board of Directors at their meeting held on April 08, 2005 considered and approved to form two Joint Ventures with Aspen Pharmacare Holdings Limited, South Africa. In this connection the Company has issued a press release titled "Matrix and Aspen, South Africa, to form two JVs". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the company has issued a press release dated April 07,2005 titled "Dr. Gopalan joins as Chief Scientific Officer (CSO)".The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the company has issued a press release dated March 23,2005 titled "Matrix to acquire major stake in MCHEM Pharma Group, China.The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the Company has issued a press release dated March 06, 2005 regarding the fire accident that took place in a production block of one of the manufacturing facilities of the company at Kazipally, near Hyderabad, on March 05, 2005. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Clarification of News : The press had reports on February 18, 2005 that Matrix Laboratories Limited is to announce it's second patent bid shortly. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Matrix Laboratories Limited has vide its letter inter-alia stated, "We hereby confirm that the said press release that appeared in the press was not release by us and also confirm that the contents were not provided by us.

Clarification of News : The press had reports that Matrix Laboratories Limited is to announce it's second patent bid shortly. The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Reply is awaited from Matrix Laboratories Limited.

Matrix Laboratories Limited has informed the Exchange that further to their communication relating to an estimated consideration of Rs.950 millions towards the settlement of a potential patent infringement suit, the Company has now informed that, as a part payment, they have received a sum of Rs.750 millions on February 16, 2005.

Matrix Laboratories Limited has informed the Exchange that the company will be receiving an estimated lump sum consideration of Rs.950 millions towards the settlement of a potential patent infringement suit.

Matrix Laboratories Limited has informed the Exchange that the Compensation Committee at its meeting held on February 05,2005 have granted 30,00,000 employee stock options of Rs.2/- each to the eligible members of the Scheme under ESOP 2004.

Matrix Laboratories Limited has informed the Exchange that the company has issued a press release dated February 07, 2005 titled 'Matrix in strategic alliance with MCHEM of China.' The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements

Matrix Laboratories Limited has informed the Exchange that the company has issued a press release dated January 27, 2005 titled 'Dr. Haseltine appointed as Chairman of Matrix Scientific Advisory Board (MSAB).' The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the BOD's at their meeting held on January 22, 2005, considered and approved the following business: 1) Appointment of Mr. Arun Duggal as an additional director of the Company; 2) Allotment of 74841605 equity shares of Rs.2/- each on Bonus Issue; 3) Annulment of forfeiture of equity shares.

Matrix Laboratories Limited has informed the Exchange that that the company has issued a press release dated January 22, 2005 titled 'Matrix labs' Gross sales at Rs.175 cr and Net profit at Rs.25.55 cr for Q3.' The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the company has issued a press release dated January 19, 2005 titled 'Matrix Labs purchases finished dosage facility.' The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has submitted to the Exchange additional information (press release) on purchase of Finished Dosage Facility. The details of the press release titled 'Matrix Labs purchases finished dosage facility' shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange regarding disclosures received from the employees of the Company for sale of shares held by them. The details are as follows: 1) Mr. V.V.Ravi Kumar has sold 1000 shares of Matrix Laboratories Limited on December 08, 2004. The mode of sale is through the open market and his shareholding after the said sale is 1276 shares representing 0.01% of the total share capital of the company.2) Mr. M.Bhaskaraiah has sold 500 shares of Matrix Laboratories Limited on December 08, 2004. The mode of sale is through the open market and his shareholding afte

Matrix Laboratories Limited has informed the Exchange that the BODs at their meeting held on December 16, 2004, have fixed January 20, 2005 as Record Date for Sub-division of Equity Shares and Bonus Issue. The Board also constituted Compensation Committee for administration and superintendence of ESOP 2004 with the following Directors: 1) Mr. Puneet Bhatia-Chairman, 2) Mr. C. Ramakrishna-Member and 3 )Mr. N. Prasad-Member.

Matrix Laboratories Limited has informed the Exchange that the company has on December 16, 2004 issued a press release titled "Matrix AGM approves Bonus issue and Stock split". The details of the press release issued by the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange regarding disclosures received from Dr. Mohan, employee of the Company. The details are as follows: 1) Dr. B Mohan has sold 500 shares on November 23, 2004. The mode of sale is through the open market and his shareholding after the said sale is 500 shares.

Matrix Laboratories Limited has informed the Exchange that the results of postal ballot conducted pursuant to the provisions of Section 192A of the Companies Act, 1956 read with Companies (Passing of resolution by postal ballot) Rules 2001 in respect to the Resolutions under Sections 17 & 81(1A) of the Companies Act, 1956 for the following business : (1) Amendment to Objects Clause of Memorandum of Association of the Company; and (2) Issue of Equity Shares, had been declared on December 02, 2004 and the results are as follows : (i) Total no. of members voted in favour of the resolution - 769 m

Matrix Laboratories Limited has informed the Exchange that the company has issued a press release on November 29,2004 on "Signing of Drug Discovery research collaboration agreement with aRigen Inc.".The details of the press release issued by the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).

Matrix Laboratories Limited has informed the Exchange that the BOD at their meeting held on October 30, 2004, have approved the following : 1) approval of the notice for convening the AGM of the company on December 16, 2004. 2) fixation of the period for book closure from December 13, 2004 to December 16, 2004 for the purpose of AGM and payment of dividend.

Matrix Laboratories Limited had informed the Exchange that the Hon'ble High Court of Andhra Pradesh has sanctioned the Scheme of Arrangement for Amalgamation amongst Vera Laboratories Limited, Fine Drugs and Chemicals Limited, Medikon Laboratories Limited and Calibre Engineering Private Limited Transferor Companies) with Matrix Laboratories Limited (Transferee Company) vide its order dated October 13, 2004. The Appointed date for merger is January 01, 2004. The Company has further informed that in line with the Scheme of Arrangement for Amalgamation, the BOD's of the Matrix Laboratories Limite

Matrix Laboratories Limited has informed the Exchange that the BOD at their meeting held on October 26, 2004 have considered and approved the following business, subject to the approval of the shareholders at the ensuing AGM : 1) Recommended final dividend of Rs.6/- per share for the financial year 2003 - 2004. 2) Sub-division (split) of equity shares of the company from the present face value of Rs.10/- each to Rs.2/- each per share. 3) Issue of Bonus shares in the ratio of 1:1.